476 related articles for article (PubMed ID: 24071566)
1. LY2456302 is a novel, potent, orally-bioavailable small molecule kappa-selective antagonist with activity in animal models predictive of efficacy in mood and addictive disorders.
Rorick-Kehn LM; Witkin JM; Statnick MA; Eberle EL; McKinzie JH; Kahl SD; Forster BM; Wong CJ; Li X; Crile RS; Shaw DB; Sahr AE; Adams BL; Quimby SJ; Diaz N; Jimenez A; Pedregal C; Mitch CH; Knopp KL; Anderson WH; Cramer JW; McKinzie DL
Neuropharmacology; 2014 Feb; 77():131-44. PubMed ID: 24071566
[TBL] [Abstract][Full Text] [Related]
2. Effects of orally-bioavailable short-acting kappa opioid receptor-selective antagonist LY2456302 on nicotine withdrawal in mice.
Jackson KJ; Jackson A; Carroll FI; Damaj MI
Neuropharmacology; 2015 Oct; 97():270-4. PubMed ID: 26044637
[TBL] [Abstract][Full Text] [Related]
3. Duration of action of a broad range of selective κ-opioid receptor antagonists is positively correlated with c-Jun N-terminal kinase-1 activation.
Melief EJ; Miyatake M; Carroll FI; Béguin C; Carlezon WA; Cohen BM; Grimwood S; Mitch CH; Rorick-Kehn L; Chavkin C
Mol Pharmacol; 2011 Nov; 80(5):920-9. PubMed ID: 21832171
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological characterization of 2-methyl-N-((2'-(pyrrolidin-1-ylsulfonyl)biphenyl-4-yl)methyl)propan-1-amine (PF-04455242), a high-affinity antagonist selective for κ-opioid receptors.
Grimwood S; Lu Y; Schmidt AW; Vanase-Frawley MA; Sawant-Basak A; Miller E; McLean S; Freeman J; Wong S; McLaughlin JP; Verhoest PR
J Pharmacol Exp Ther; 2011 Nov; 339(2):555-66. PubMed ID: 21821697
[TBL] [Abstract][Full Text] [Related]
5. Determining pharmacological selectivity of the kappa opioid receptor antagonist LY2456302 using pupillometry as a translational biomarker in rat and human.
Rorick-Kehn LM; Witcher JW; Lowe SL; Gonzales CR; Weller MA; Bell RL; Hart JC; Need AB; McKinzie JH; Statnick MA; Suico JG; McKinzie DL; Tauscher-Wisniewski S; Mitch CH; Stoltz RR; Wong CJ
Int J Neuropsychopharmacol; 2014 Oct; 18(2):. PubMed ID: 25637376
[TBL] [Abstract][Full Text] [Related]
6. Safety, tolerability, and pharmacokinetic evaluation of single- and multiple-ascending doses of a novel kappa opioid receptor antagonist LY2456302 and drug interaction with ethanol in healthy subjects.
Lowe SL; Wong CJ; Witcher J; Gonzales CR; Dickinson GL; Bell RL; Rorick-Kehn L; Weller M; Stoltz RR; Royalty J; Tauscher-Wisniewski S
J Clin Pharmacol; 2014 Sep; 54(9):968-78. PubMed ID: 24619932
[TBL] [Abstract][Full Text] [Related]
7. Identification of (3R)-7-hydroxy-N-((1S)-1-[[(3R,4R)-4-(3-hydroxyphenyl)- 3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl)-1,2,3,4-tetrahydro- 3-isoquinolinecarboxamide as a novel potent and selective opioid kappa receptor antagonist.
Thomas JB; Atkinson RN; Vinson NA; Catanzaro JL; Perretta CL; Fix SE; Mascarella SW; Rothman RB; Xu H; Dersch CM; Cantrell BE; Zimmerman DM; Carroll FI
J Med Chem; 2003 Jul; 46(14):3127-37. PubMed ID: 12825951
[TBL] [Abstract][Full Text] [Related]
8. Differential effects of the novel kappa opioid receptor antagonist, JDTic, on reinstatement of cocaine-seeking induced by footshock stressors vs cocaine primes and its antidepressant-like effects in rats.
Beardsley PM; Howard JL; Shelton KL; Carroll FI
Psychopharmacology (Berl); 2005 Nov; 183(1):118-26. PubMed ID: 16184376
[TBL] [Abstract][Full Text] [Related]
9. Pharmacological properties of JDTic: a novel kappa-opioid receptor antagonist.
Carroll I; Thomas JB; Dykstra LA; Granger AL; Allen RM; Howard JL; Pollard GT; Aceto MD; Harris LS
Eur J Pharmacol; 2004 Oct; 501(1-3):111-9. PubMed ID: 15464069
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis and biological evaluation of aminobenzyloxyarylamide derivatives as selective κ opioid receptor antagonists.
Wang J; Song Q; Xu A; Bao Y; Xu Y; Zhu Q
Eur J Med Chem; 2017 Apr; 130():15-25. PubMed ID: 28237793
[TBL] [Abstract][Full Text] [Related]
11. Behavioral Pharmacology of Novel Kappa Opioid Receptor Antagonists in Rats.
Page S; Mavrikaki MM; Lintz T; Puttick D; Roberts E; Rosen H; Carroll FI; Carlezon WA; Chartoff EH
Int J Neuropsychopharmacol; 2019 Nov; 22(11):735-745. PubMed ID: 31613314
[TBL] [Abstract][Full Text] [Related]
12. Discovery of the first small-molecule opioid pan antagonist with nanomolar affinity at mu, delta, kappa, and nociceptin opioid receptors.
Zaveri NT; Journigan VB; Polgar WE
ACS Chem Neurosci; 2015 Apr; 6(4):646-57. PubMed ID: 25635572
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and in vitro opioid receptor functional antagonism of analogues of the selective kappa opioid receptor antagonist (3R)-7-hydroxy-N-((1S)-1-{[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl}-2-methylpropyl)-1,2,3,4-tetrahydro-3-isoquinolinecarboxamide (JDTic).
Cai TB; Zou Z; Thomas JB; Brieaddy L; Navarro HA; Carroll FI
J Med Chem; 2008 Mar; 51(6):1849-60. PubMed ID: 18307295
[TBL] [Abstract][Full Text] [Related]
14. Antidepressant-like effects of kappa-opioid receptor antagonists in the forced swim test in rats.
Mague SD; Pliakas AM; Todtenkopf MS; Tomasiewicz HC; Zhang Y; Stevens WC; Jones RM; Portoghese PS; Carlezon WA
J Pharmacol Exp Ther; 2003 Apr; 305(1):323-30. PubMed ID: 12649385
[TBL] [Abstract][Full Text] [Related]
15. Opioid peptide receptor studies. 12. Buprenorphine is a potent and selective mu/kappa antagonist in the [35S]-GTP-gamma-S functional binding assay.
Romero DV; Partilla JS; Zheng QX; Heyliger SO; Ni Q; Rice KC; Lai J; Rothman RB
Synapse; 1999 Nov; 34(2):83-94. PubMed ID: 10502307
[TBL] [Abstract][Full Text] [Related]
16. A novel, potent, oral active and safe antinociceptive pyrazole targeting kappa opioid receptors.
Trevisan G; Rossato MF; Walker CI; Oliveira SM; Rosa F; Tonello R; Silva CR; Machado P; Boligon AA; Martins MA; Zanatta N; Bonacorso HG; Athayde ML; Rubin MA; Calixto JB; Ferreira J
Neuropharmacology; 2013 Oct; 73():261-73. PubMed ID: 23791558
[TBL] [Abstract][Full Text] [Related]
17. Chronic pain induces anxiety with concomitant changes in opioidergic function in the amygdala.
Narita M; Kaneko C; Miyoshi K; Nagumo Y; Kuzumaki N; Nakajima M; Nanjo K; Matsuzawa K; Yamazaki M; Suzuki T
Neuropsychopharmacology; 2006 Apr; 31(4):739-50. PubMed ID: 16123756
[TBL] [Abstract][Full Text] [Related]
18. Kappa1- and kappa2-opioid receptors mediating presynaptic inhibition of dopamine and acetylcholine release in rat neostriatum.
Schoffelmeer AN; Hogenboom F; Mulder AH
Br J Pharmacol; 1997 Oct; 122(3):520-4. PubMed ID: 9351509
[TBL] [Abstract][Full Text] [Related]
19. Repeated Administration of Opra Kappa (LY2456302), a Novel, Short-Acting, Selective KOP-r Antagonist, in Persons with and without Cocaine Dependence.
Reed B; Butelman ER; Fry RS; Kimani R; Kreek MJ
Neuropsychopharmacology; 2018 Mar; 43(4):739-750. PubMed ID: 28857070
[TBL] [Abstract][Full Text] [Related]
20. Differential antagonism of U69,593- and bremazocine-induced antinociception by (-)-UPHIT: evidence of kappa opioid receptor multiplicity in mice.
Horan P; de Costa BR; Rice KC; Porreca F
J Pharmacol Exp Ther; 1991 Jun; 257(3):1154-61. PubMed ID: 1646325
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
